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Abstract 
Primary sclerosing cholangitis (PSC) is an autoimmune disease of the hepatobiliary 
system for which effective therapy has not been established. Leukocytapheresis (LCAP) 
therapy is known to effective in patients with ulcerative colitis (UC). In addition, effects 
of LCAP therapy were reported on some autoimmune diseases such as Crohn’s disease, 
rheumatoid arthritis and rapidly progressive glomerulonephritis. Here we report the case 
of a 29-year-old man with PSC associated with UC who was treated with LCAP therapy. 
He had a 16-year history of UC and a 12-year history of PSC. Although he was under 
treatment with prednisolone and ursodeoxycholic acid, exacerbation of UC and 
PSC-associated cholestasis were seen. Since he showed side effects of prednisolone, he 
was treated with LCAP. Not only improvement of UC, but also decreased serum alkaline 
phosphatase, γ-guanosine triphosphate and total bile acids, suggesting improvement of 
PSC-associated cholestaisis, were seen after treatment with LCAP. Our experience with 
this case suggests that LCAP therapy could be a new effective therapeutic strategy for 
patients with PSC associated with UC. 
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Introduction 
Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease of unknown 
etiology. It is characterized by inflammation and fibrosis of the biliary tree, with eventual 
liver cirrhosis and a high risk of cholangiocarcinoma. PSC may occur in the presence or 
absence of inflammatory bowel disease. The prevalence of inflammatory bowel disease 
(typically ulcerative colitis, UC) among PSC patients is approximately 70–80%, whereas 
only 2–7.5% of patients with UC will develop PSC [1]. Although therapeutic trials of 
ursodeoxycholic acid, D-penicillamine, tacrolimus, corticosteroids, azathioprine [2], 
methotrexate and bezafibrate have been conducted [1], effective medical therapy has not 
been shown to alter the progressive course of PSC. While liver transplantation is regarded 
as the only life-extending therapeutic alternative for patients with PSC, the disease has 
also been known to recur after transplantation [3, 4]. 
Recently, leukocytapheresis (LCAP) therapy has been shown to improve the 
exacerbation of UC. The effectiveness of LCAP on Crohn’s disease, rheumatoid arthritis, 
and rapidly progressive glomerulonephritis is also reported [5]. Furthermore, it is 
reported that LCAP is effective for extraintestinal complications of inflammatory bowel 
disease, including pyoderma gangrenosum [6] and aortitis syndrome [7]. However, there 
are as yet no reports on the efficacy of LCAP for PSC associated with UC. Here, we report 
the first patient with PSC in whom LCAP improved cholestasis. 
Case Report 
A 29-year-old male was under regular treatment at the outpatient department of our hospital for UC 
with PSC. The patient, who suffered from abdominal pain and bloody mucus diarrhea since he was 
10 years of age, was diagnosed by colonoscopy to have active UC, and treatment with prednisolone was 
initiated. At age 14, laboratory tests showed mild abnormalities of liver function parameters, with 
elevated serum levels of biliary enzymes, including alkaline phosphatase (ALP) and γ-guanosine 
triphosphate (γ-GTP). Abdominal ultrasonography and computed tomography revealed multiple 
strictures and dilatation of the intra- and extrahepatic bile ducts. Endoscopic retrograde 
cholangiopancreatography showed pathognomonic strictures of the intra- and extrahepatic bile ducts, 
giving a ‘beads-on-a-string’ appearance (fig. 1a). Diagnostic imaging such as abdominal 
ultrasonography, computed tomography, endoscopic retrograde cholangiopancreatography, magnetic 
resonance imaging and magnetic resonance cholangiopancreatography showed no malignancy of the 
bile duct. In addition, stone disease, bacterial infection, pancreatitis, or surgical/procedural trauma was 
not seen. Furthermore, laboratory data showed negative results of various autoantibodies such as 
antimitochondrial antibody, antinuclear antibody, and myeloperoxidase antineutrophil cytoplasmic 
antibody. The specimen of liver biopsy showed concentric layers of fibrotic tissue surrounding the bile 
duct lesions, the bile duct at the center was infiltrated with neutrophils and lymphocytes and epithelial 
cells were damaged. Proliferation of the bile ducts were also seen (fig. 1b) [8, 9]. We diagnosed this case 
as PSC associated with UC by the criteria of the Mayo clinic [9]. Treatment with ursodeoxycholic acid 
was initiated, and subsequently the patient was followed up at our hospital with occasional relapses of 
UC and gradual worsening of PSC. 
At age 29, the patient began to complain again of abdominal pain and bloody mucus diarrhea. 
Although treatment with ursodeoxycholic acid at a dose of 600 mg/day and prednisolone at a dose of 
5 mg/day was continued, no improvement was noted. Colonoscopy was performed, which revealed 
evidence of active UC with diffuse mucosal inflammation and ulcerations in the left-sided colon. 
Simultaneously, laboratory tests showed elevated serum levels of biliary enzymes, including ALP and 
γ-GTP, and of total bile acid and total bilirubin levels, indicating exacerbation of the PSC (table 1). 
Magnetic resonance cholangiopancreatography showed a typical ‘beads-on-a-string’ appearance (fig. 2) 
and there were no findings suggesting malignancy, stone or secondary cholangitis. Neither were 
pathogenic bacteria detected in feces cultivation. The patient had been treated with a total of more than 
20 g of prednisolone since he was diagnosed with UC. In order to avoid the occurrence of side effects, he 
was not likely to tolerate additional steroid therapy. In fact, his mineral quantitation by digital image 
processing indicated osteoporosis, and oral candidiasis was seen. Under these circumstances, LCAP  
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therapy was initiated with once-a-week sessions for five weeks. LCAP was performed using a 
Cellsorba E column (Asahi Medical, Tokyo, Japan) installed in the extracorporeal circulation system 
(Plasauto LC, Asahi Medical) [10]. For apheresis, venous access was secured via two large peripheral 
veins, and the blood was anticoagulated with nafamostat mesilate (Torii Pharmaceutical, Tokyo, Japan), 
a protease inhibitor that inhibits the activity of coagulation factors and platelet aggregation. With a flow 
rate of 30–50 ml/min for 60 min, a total of approximately 2.5 l of blood was treated during each session. 
Previous data show that nearly 100% of neutrophils and monocytes that entered the filter, and 40–60% 
of lymphocytes were removed in one session of LCAP [11]. Marked improvement of both the clinical 
symptoms and colonoscopic findings of UC were noted in response to LCAP therapy. Serum levels of 
ALP, total bile acids and total bilirubin were decreased (fig. 3). Follow-up of the patient revealed no 
exacerbation of disease activity for either UC or PSC for more than one year. 
Discussion 
We experienced a patient with UC complicated by PSC who underwent LCAP and 
showed improvement not only in clinical signs and colonoscopic findings of UC, but also 
in PSC-associated cholestasis. The patient has been treated with a total of more than 20 g 
of prednisolone since he was diagnosed with UC. In order to avoid occurrence of side 
effects, he was not likely to tolerate additional steroid therapy. In fact, his mineral 
quantitation by digital image processing indicated osteoporosis, and oral candidiasis was 
seen. Therefore, we selected LCAP therapy. 
There are at least two possible mechanisms underlying the improvement of PSC 
associated in this patient. One possibility is that the PSC may have improved via a 
mechanism similar to that underlying the improvement of UC [1]. As to the mechanism 
underlying the action of LCAP in UC, previous reports have described beneficial effects 
including suppression of proinflammatory cytokine release from leukocytes [12] and 
induction of bone marrow cells to repair the impaired intestine. Similar effects may also 
have been exerted in the impaired bile tract. The other possibility is that improvement of 
PSC may have been secondary to improvement of UC [13]. Some reports have shown that 
the impairment of intestinal mucosal integrity observed in UC may lead to the passage of 
luminal antigens into the portal vein, thereby leading to the development of PSC [14]. 
According to this possibility, treatment of UC by LCAP may improve PSC. However, we 
have to be cautious with the interpretation of cholestasis improvement. In previous 
reports, the improvement of PSC was evaluated using laboratory data: ALP, aspartate 
aminotransferase, total bilirubin and albumin [15]. However, the definition of 
improvement in PSC should not solely rely on laboratory data. In this case, there was no 
significant change in organic stricture of the bile duct after LCAP therapy. Although 
minimal improvement in bile the ducts may occur with LCAP therapy, we cannot deny 
the possibility of an effect due to the improvement of UC. 
In conclusion, we conducted LCAP in a patient with PSC associated with UC. He 
showed improvement not only in UC, but also in PSC. No effective therapy for PSC is 
known at present. Improvement of PSC-associated cholestasis was seen in this case. 
Therefore LCAP may be a new effective therapeutic strategy for PSC associated with UC. 
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Table 1. Laboratory data at relapse of UC 
WBC  9,000 /ml  ALT  44 U/l 
RBC 547  ×10
3/ml LDH  144  U/l 
Hb  11.8 g/100 ml  ALP  553 U/l 
HCT 38.7%  γ-GTP  98  U/l 
MCV  70.7 fl  TB  0.7 mg/100 ml 
MCH  21.6 pg  DB  0.09 mg/100 ml 
MCHC  30.5 g/100 ml  TBA  114.4 μmol/l 
PLT  42.9 × 10
3/ml  TP  7.54 g/100 ml 
PT  82%  ALB  4.06 g/100 ml 
CRP  0.23 mg/100 ml  TTT  16.7 U/l 
HBs-Ag Negative  ZTT  17  U/l 
HCV-Ab  Negative  BUN  8.3 mg/100 ml 
HIV-Ab  Negative  Cr  0.76 mg/100 ml 
ANA Negative  Na  140  mEq/l 
AMA Negative  K  4.1  mEq/l 
MPO-ANCA Negative  Cl  106  mEq/l 
AST 30  U/l     
WBC = White blood cells; RBC = red blood cells; Hb = hemoglobin; HCT = hematocrit; MCV = mean 
corpuscular volume; MCH = mean corpuscular hemoglobin; MCHC = mean corpuscular hemoglobin 
concentration; PLT = platelet count; PT = prothrombin time; CRP = C-reactive protein; HBs-Ag = 
hepatitis B surface antigen; HCV-Ab = hepatitis C virus antibody; HIV-Ab = human immunodeficiency 
virus antibody; ANA = antinuclear antibody; AMA = antimitochondrial antibody; MPO-ANCA = 
myeloperoxidase antineutrophil cytoplasmic antibody; AST = aspartate aminotransferase; ALT = alanine 
aminotransferase; LDH = lactate dehydrogenase; ALP = alkaline phosphatase, lactic dehydrogenase; 
γ-GTP = γ-guanosine triphosphate; TB = total bilirubin; DB = direct bilirubin; TBA = total bile acids; 
TP = total protein; ALB = serum albumin; TTT = thymol turbidity test; ZTT = zinc sulfate turbidity test; 
BUN = blood urea nitrogen; Cr = creatinine; Na = sodium ion; K = potassium ion; Cl = chloride. 
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Fig. 1. a Endoscopic retrograde cholangiopancreatography shows pathognomonic stricture of intra- 
and extrahepatic bile ducts and ‘beads-on-a-string’ appearance. b Liver biopsy shows concentric layers 
of fibrotic tissue surrounding the bile duct lesions (arrow); the bile duct at the center is infiltrated with 
neutrophils and lymphocytes and epithelial cells are damaged. Proliferation of the bile ducts is also seen. 
 
 
 
Fig. 2. Magnetic resonance cholangiopancreatography shows pathognomonic stricture of the intra- 
and extrahepatic bile ducts and no malignancy or cholecystolithiasis. 
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Fig. 3. The effect of LCAP on exacerbation of PSC-associated cholestasis. Exacerbation of 
PSC-associated cholestasis occurred after relapse of UC. Abnormality in serum ALP, γ-GTP, total 
bilirubin and total bile acids gradually decreased over the course of five LCAP procedures. 
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